Economic evaluations in Italy: A review of the literature

International Journal of Technology Assessment in Health Care

Volumn 19, Issue 4, 2003, Pages 685-691

  Garattini, Livio ^a   De Compadri, Paola ^a   Clemente, Rosamaria ^a   Cornago, Dante ^a  

^a Centre for Health Economics   (United States)

Author keywords

Economic evaluation; Italy; Methodology; Review

Indexed keywords

DATABASE SYSTEMS; DRUG DOSAGE; ECONOMIC AND SOCIAL EFFECTS; INDUSTRIAL ECONOMICS; PHARMACODYNAMICS;

ECONOMIC EVALUATIONS (EE); HEALTH ECONOMICS;

HEALTH CARE;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DATA BASE; ECONOMIC ASPECT; EMBASE; EVALUATION; HUMAN; ITALY; MEDICAL RESEARCH; MEDLINE; REVIEW; STATISTICAL ANALYSIS; TECHNIQUE;

COSTS AND COST ANALYSIS; DELIVERY OF HEALTH CARE; ECONOMICS, PHARMACEUTICAL; EVALUATION STUDIES; HEALTH CARE COSTS; ITALY;

EID: 1642541979     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462303000643     Document Type: Review

References (24)

1. Attanasio E, Bruzzi P, Capri S, et al. Raccomandazioni per la conduzione degli studi di farmacoeconomia: La guida GISF. Mecosan. 1999;29:65-72.
2. Colombo GL, Serra G, Terranova L. Indagine sulla diffusione della farmaeconomia nell'industria farmaceutica che opera in Italia. Pharmacoeconomics. 2001;3:91-103.
3. De Pouvourville G. Changes in health economic data bases. Hepac. 2000;1:93.
4. Drummond MF, Jönsson B, Rutten FFH. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy. 1997;40:199-215.
5. Drummond MF, Dubois D, Garattini L, et al. Current trends in the use of pharmacoeconomics and outcomes research in Europe. Value Health. 1999;2:323-332.
6. Drummond MF. Cost of Illness studies. A major headache? Pharmacoeconomics. 1992;2:1-4.
7. Drummond MF. A reappraisal of economic evaluations of pharmaceuticals: Science or Marketing? Pharmacoeconomics. 1998;14:1-9.
8. Fattore G, Jommi C. The new pharmaceutical policy in Italy. Health Policy. 1998;46:21-41.
9. Garattini L, Tediosi F, Ghislandi S, Orzella L, Rossi C. How do Italian pharmacoeconomists evaluate indirect costs. Value Health. 2000;3:270-276.
10. Garattini L, Grilli R, Scopelliti D, et al. A proposal for Italian guidelines in pharmacoeconomics. Pharmacoeconomics. 1995;7:1-6.
11. Garcìa-Altés A. Twenty years of health care economic analysis in Spain: Are we doing well? Health Econ. 2001;10:715-729.
12. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines: Similarities, differences and some implications. Value Health. 2001;4:225-250.
13. Koopmanschap MA. Cost of illness studies: Useful for health policy? Pharmacoeconomics. 1998;14:143-148.
14. Krimsky S. Conflict of interest and cost-effectiveness analysis. JAMA. 1999;282:1474-1475.
15. Morgan S, Barer M, Evans R. Health economists meet the fourth tempter: Drug dependency and scientific discourse. Health Econ. 2000;9:659-667.
16. Nixon J, Stoykova B, Glanville J, et al. The U.K. NHS economic evaluation database. Int J Technol Assess in Health Care. 2000;16:731-742.
17. OHE-IFPMA. Health Economic Evaluation Database (HEED). London: Office for Health Economics; 1999.
18. Pritchard C. What do we know about the economic evaluation literature? A review of HEED. J Drug Assess. 2001;4:9-20.
19. Rennie D, Luft H. Pharmacoeconomic analysis: Making them transparent, making them credible. JAMA. 2000;283:2158-2160.
20. Rittenhouse BE. Is there a need for standardization of methods in economic evaluations of medicines? Med Care. 1996;34:DS13-DS22.
21. Sloan F. Valuing health care. Cambridge: Cambridge University Press; 1995.
22. Societâ Italiana di FarmacoEconomia (SIFE). Linee guida per la conduzionedi studi sull'efficacia e sul costo dei trattamenti farmacologici. Giornale Farmacoeconomia. 1999;3:147-153.
23. Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology: A report on principles. Ann Intern Med. 1995;122:61-70.
24. Ulmann P. The CODECS Project. Hepac. 2000;1:129-130.